Rising Star Outreach of India

Visit site

Maharashtra Dayanand Society

Visit site

Little Flower Leprosy Welfare Association

Guam Department of Public Health and Social Services

Visit site

Salt Water Tours

2 November 2022 · Global Partnership for Zero Leprosy

The Task Force for Global Health Statement at the 73rd WHO Regional Committee Meeting for the Western Pacific

The Global Partnership For Zero Leprosy, a program of the Task Force for Global Health, submitted a statement to the 73rd World Health Organization (WHO) Regional Committee Meeting for the Western Pacific in October 2022. The statement refers to agenda item 14, “Reaching the unreached.” … Read More >

UN Special Rapporteur Factsheet: Why Inclusive Participation Matters

This factsheet distills the key messages of the UN Special Rapporteur’s October 2022 report, “Multiple disabilities and fluid self-identification: disability rights of persons affected by leprosy and their family members and how they challenge national legal frameworks.”


Yayasan Dedikasi Tjipta Indonesia (YDTI)

Todu Guam Foundation

Visit site

The Leprosy Mission Bangladesh

The Center for Tuberculosis & Leprosy Control (Botswana) Trust

Sorok Uni Foundation Inc.

Shanti Rehabilitation Center

PerMaTa Indonesia South Sulawesi

John and Friends Healthcare Foundation

Centre d’Infectiologie Charles Mérieux – University of Antananarivo

Asosiasaun Ema Afeita Lepra Timor Leste

Global leprosy (Hansen disease) update, 2021: moving towards interruption of transmission

WHO collects statistics on leprosy annually from countries to assess the situation and to publish an annual global leprosy update. In 2021, 143 countries provided statistics, as compared with 127 in 2020.


Improving funding transparency to advance leprosy research

A letter to the editor published in the September 2022 issue of Leprosy Review.

Visit site

Factsheet on SDR-PEP: The latest research on single-dose rifampicin post-exposure prophylaxis

Single-dose rifampicin post-exposure prophylaxis (SDR-PEP) is a preventive treatment for leprosy that can be used to reduce the risk of developing leprosy among contacts of leprosy patients and thus, indirectly, reduce transmission of leprosy bacilli. Large-scale, international studies show that SDR-PEP is safe and contributes to reducing leprosy incidence and preventing secondary disabilities. It has been tested in more than 11 countries, and more than 175,000 people have received treatment in research settings. The World Health Organization (WHO) advises the use of SDR-PEP in the Roadmap for Neglected Tropical Diseases 2021 – 2030, the Global Leprosy Strategy, and the WHO Guidelines for the Diagnosis, Treatment, and Prevention of Leprosy. The Global Partnership for Zero Leprosy also recommends SDR-PEP for routine leprosy control services.